Abstract: The present invention relates absorbent article having a wearer facing surface and a garment facing surface, the absorbent article comprising: a topsheet, a backsheet, and a layer of absorbent material disposed between the topsheet and the backsheet, wherein the topsheet comprises a first layer comprising cellulose-based fibers, the first layer comprising a first surface, an opposite second surface, and a plurality of apertures having side walls, wherein the first surface of the first layer forms at least part of the wearer facing surface; wherein the first surface of the first layer comprises at least one non-aperture area having a first non-aperture area contact angle as measured by Contact Angle Test; and wherein each of majority of the apertures has a side wall having an aperture contact angle as measured by Contact Angle Test, the aperture contact angle being higher than the first non-aperture area contact angle.

Abstract: The present invention relates to a three-dimensional nonwoven comprising a first side, a second side, a protruded first area comprising an upper portion formed in the first side and a lower portion formed in the second side, and a second area comprising a plurality of deformations, wherein the upper portion has a shape memory index higher than a shape memory index of the lower portion, an absorbent article comprising the three-dimensional nonwoven, and a process for producing the three-dimensional nonwoven.

Abstract: Methods are provided to improve the positive predictive value for cancer detection using cell-free nucleic acid samples. Various embodiments are directed to applications (e.g., diagnostic applications) of the analysis of the fragmentation patterns and size of cell-free DNA, e.g., plasma DNA and serum DNA, including nucleic acids from pathogens, including viruses. Embodiments of one application can determine if a subject has a particular condition. For example, a method of present disclosure can determine if a subject has cancer or a tumor, or other pathology. Embodiments of another application can be used to assess the stage of a condition, or the progression of a condition over time. For example, a method of the present disclosure may be used to determine a stage of cancer in a subject, or the progression of cancer in a subject over time (e.g., using samples obtained from a subject at different times).

Abstract: The present disclosure relates to a cell-free DNA-based cancer diagnosis model and use. A first aspect of the present disclosure provides a construction method for a cancer diagnosis model, including the steps of obtaining sequencing data of cell-free DNA of a non-cancer population; comparing the sequencing data of the cell-free DNA of the non-cancer population with reference genomes to obtain corresponding sites of the ends of the cell-free DNA on the reference genomes; and constructing the cancer diagnosis model based on the corresponding sites of the ends of the cell-free DNA on target genome intervals. The present disclosure adopts an idea that is opposite to the prevailing method. Instead of trying to identify diagnostic markers based on the specific fragmentation patterns of tumor cfDNA, the applicant constructs the cancer diagnosis model by looking for the end distribution patterns of cfDNA in non-cancer population.

Abstract: Systems, apparatuses, and method are provided for determining the contributions of different tissues to a biological sample that includes a mixture of cell-free DNA molecules from various tissues types, e.g., as occurs in plasma or serum and other body fluids. Embodiments can analyze the methylation patterns of the DNA mixture (e.g., methylation levels at particular loci) for a particular haplotype and determine fractional contributions of various tissue types to the DNA mixture, e.g., of fetal tissue types or tissue types of specific organs that might have a tumor. Such fractional contributions determined for a haplotype can be used in a variety of ways.

Abstract: The present invention relates to an apparatus for deforming a web to created deformed nonwoven which comprises a pair of counter-rotating rolls that form a nip therebetween, the pair of rolls comprising: a first roll comprising a surface, a plurality of protrusions extending radially outwardly from the surface of the first roll, and a plurality of concaves formed inwardly from the surface of the first roll; and a second roll comprising a surface; and a process for producing a deformed web comprising the steps of (a) forming a fibrous web; (b) subjecting the fibrous web to bonding treatment to bond at least part of fibers constituting the fibrous web to obtain a precursor nonwoven; and (c) subjecting the precursor nonwoven to a deformation forming unit comprising an apparatus according to the present invention.

Abstract: Various applications can use fragmentation patterns related of cell-free DNA, e.g., plasma DNA and serum DNA. For example, the end positions of DNA fragments can be used for various applications. The fragmentation patterns of short and long DNA molecules can be associated with different preferred DNA end positions, referred to as size-tagged preferred ends. In another example, the fragmentation patterns relating to tissue-specific open chromatin regions were analyzed. A classification of a proportional contribution of a particular tissue type can be determined in a mixture of cell-free DNA from different tissue types. Additionally, a property of a particular tissue type can be determined, e.g., whether a sequence imbalance exists in a particular region for a tissue type or whether a pathology exists for the tissue type.

Abstract: Methods and systems are provided for security patch type detection of software patches. A software patch for a software product may be received. For example, the software patch may be received by a computing device. A pre-patch code property graph and a post-patch code property graph may be determined. For example, the pre-patch code property graph and the post-patch code property graph may be determined based on the software patch and/or the pre-patch source code and the post-patch source code respectively. A combined patch code property graph may be determined. For example, the combined patch code property graph may be determined based on the pre-patch code property graph and the post-patch code property graph. A patch type for the software patch may be determined. For example, the patch type may be determined based on the combined patch code property graph and/or a machine-learning prediction model.

Abstract: The present disclosure describes techniques for measuring quantities (e.g., relative frequencies) of sequence end motifs of cell-free DNA fragments in a biological sample of an organism for measuring a property of the sample (e.g., fractional concentration of clinically-relevant DNA) and/or determining a condition of the organism based on such measurements. Different tissue types exhibit different patterns for the relative frequencies of the sequence end motifs. The present disclosure provides various uses for measures of the relative frequencies of sequence end motifs of cell-free DNA, e.g., in mixtures of cell-free DNA from various tissues. DNA from one of such tissue may be referred to as clinically-relevant DNA.

Abstract: The contributions of different tissues to a DNA mixture are determined using methylation levels at particular genomic sites. Tissue-specific methylation levels of M tissue types can be used to deconvolve mixture methylation levels measured in the DNA mixture, to determine fraction contributions of each of the M tissue types. Various types of genomic sites can be chosen to have particular properties across tissue types and across individuals, so as to provide increased accuracy in determining contributions of the various tissue types. The fractional contributions can be used to detect abnormal contributions of a particular tissue, indicating a disease state for the tissue. A differential in fractional contributions for different sizes of DNA fragments can also be used to identify a diseased state of a particular tissue. A sequence imbalance for a particular chromosomal region can be detected in a particular tissue, e.g., identifying a location of a tumor.

Abstract: Techniques are provided for detecting hematological disorders using cell-free DNA in a blood sample, e.g., using plasma or serum. For example, an assay can target one or more differentially-methylated regions specific to a particular hematological cell lineage (e.g., erythroblasts). A methylation level can be quantified from the assay to determine an amount of methylated or unmethylated DNA fragments in a cell-free mixture of the blood sample. The methylation level can be compared to one or more cutoff values, e.g., that correspond to a normal range for the particular hematological cell lineage as part of determining a level of a hematological disorder.

Abstract: A process for producing a deformed nonwoven is described. The process includes the steps of: adjusting a water content of a nonwoven such that the nonwoven has at least one area having a water content of at least about 12% by weight of the nonwoven in the area, and subjecting the nonwoven to a mechanical deformation process. The deformation process is a mechanical deformation of the nonwoven and dewatering of the nonwoven to obtain a deformed nonwoven.

Abstract: The present disclosure relates to a nonwoven substrate having a top surface and an opposite bottom surface, and comprising a plurality of apertures, wherein the top surface has a first contact angle of no lower than about 90 degrees as measured according to Contact Angle Test, wherein the bottom surface has a second contact angle of lower than about 90 degrees as measured according to Contact Angle Test, and wherein the plurality of apertures comprise at least one aperture having at least three adjacent apertures that are spaced apart from by an edge-to-edge space no greater than about 2.5 mm. Also disclosed herein is an absorbent article having a topsheet comprising the nonwoven substrate.

Abstract: The present disclosure relates to a nonwoven substrate having a top surface and an opposite bottom surface comprising: an upper layer forming the top surface of the nonwoven substrate, the upper layer comprising hydrophobic fibers, and a lower layer forming the bottom surface of the nonwoven substrate, the lower layer comprising hydrophilic fibers, wherein the top surface of the nonwoven substrate has a first contact angle of no lower than about 90 degrees as measured according to Contact Angle Test, wherein the bottom surface of the nonwoven substrate has a second contact angle of lower than about 90 degrees as measured according to Contact Angle Test, wherein the nonwoven has a unitary structure, and wherein the upper layer has a thickness no greater than about 1400 ?m as measured according to the Thickness Test.

Abstract: A preparation method of drug-loaded micelles of an absorbable vascular stent coating for angiostenosis in an infant is provided, including the following steps: S1: dissolving a drug to be encapsulated in an appropriate amount of an emulsifying agent, adding a chitosan-poly(p-dioxohone) amphiphilic block copolymer (chitosan-b-PPDO copolymer), and thoroughly mixing to obtain a drug-copolymer solution; S2: adding the drug-copolymer solution obtained in S1 dropwise to an emulsifying agent aqueous solution prepared in advance, and continuously stirring to obtain a stable drug-loaded micellar solution; and S3: removing the emulsifying agent from the micellar solution obtained in S2 through vacuum evaporation, stirring a resulting concentrate, and centrifuging the concentrate to obtain a supernatant; and filtering the supernatant to obtain a filtrate, and subjecting the filtrate to dialysis to obtain the drug-loaded micelles.

Abstract: The contributions of different tissues to a DNA mixture are determined using methylation levels at particular genomic sites. Tissue-specific methylation levels of M tissue types can be used to deconvolve mixture methylation levels measured in the DNA mixture, to determine fraction contributions of each of the M tissue types. Various types of genomic sites can be chosen to have particular properties across tissue types and across individuals, so as to provide increased accuracy in determining contributions of the various tissue types. The fractional contributions can be used to detect abnormal contributions of a particular tissue, indicating a disease state for the tissue. A differential in fractional contributions for different sizes of DNA fragments can also be used to identify a diseased state of a particular tissue. A sequence imbalance for a particular chromosomal region can be detected in a particular tissue, e.g., identifying a location of a tumor.

Abstract: A preparation method of drug-loaded micelles of an absorbable vascular stent coating for angiostenosis in an infant is provided, including the following steps: Si: dissolving a drug to be encapsulated in an appropriate amount of an emulsifying agent, adding a chitosan-poly(p-dioxohone) amphiphilic block copolymer (chitosan-b-PPDO copolymer), and thoroughly mixing to obtain a drug-copolymer solution; S2: adding the drug-copolymer solution obtained in S1 dropwise to an emulsifying agent aqueous solution prepared in advance, and continuously stirring to obtain a stable drug-loaded micellar solution; and S3: removing the emulsifying agent from the micellar solution obtained in S2 through vacuum evaporation, stirring a resulting concentrate, and centrifuging the concentrate to obtain a supernatant; and filtering the supernatant to obtain a filtrate, and subjecting the filtrate to dialysis to obtain the drug-loaded micelles.

Abstract: The present invention relates absorbent article having a wearer facing surface and a garment facing surface, the absorbent article comprising: a topsheet, a backsheet, and a layer of absorbent material disposed between the topsheet and the backsheet, wherein the topsheet comprises a first layer comprising cellulose-based fibers, the first layer comprising a first surface, an opposite second surface, and a plurality of apertures having side walls, wherein the first surface of the first layer forms at least part of the wearer facing surface; wherein the first surface of the first layer comprises at least one non-aperture area having a first non-aperture area contact angle as measured by Contact Angle Test; and wherein each of majority of the apertures has a side wall having an aperture contact angle as measured by Contact Angle Test, the aperture contact angle being higher than the first non-aperture area contact angle.

Abstract: Techniques are provided for detecting hematological disorders using cell-free DNA in a blood sample, e.g., using plasma or serum. For example, an assay can target one or more differentially-methylated regions specific to a particular hematological cell lineage (e.g., erythroblasts). A methylation level can be quantified from the assay to determine an amount of methylated or unmethylated DNA fragments in a cell-free mixture of the blood sample. The methylation level can be compared to one or more cutoff values, e.g., that correspond to a normal range for the particular hematological cell lineage as part of determining a level of a hematological disorder.

Abstract: An apertured nonwovens having a first nonwoven layer is described. The first nonwoven layer includes cellulose-based fibers and a plurality of apertures, wherein the plurality apertures have a minimum aperture distance between two adjacent apertures which has a relative standard deviation no greater than about 40%, as measured according to the Aperture Quality Test. The apertures have an aperture size no greater than about 2.2 mm2 and have an occlusion no greater than about 9%, as measured according to the Aperture Quality Test, or the apertures have an aspect ratio no greater than about 2.5 as measured according to the Aspect Ratio Test.